Glenmark Pharmaceuticals has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for its formulations manufacturing facility in Goa, India with a Voluntary Action Indicated (VAI) status.
The inspection was conducted at the company’s manufacturing facility from June 22, 2026 to June 30, 2026.
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy